Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera - Report - MDSpire

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera

  • By

  • A. Angona

  • B. Cuevas

  • M. Pérez-Encinas

  • F. Ferrer-Marin

  • A. Senín

  • E. Arellano-Rodrigo

  • J. C. Hernández-Boluda

  • M. I. Mata Vázquez

  • G. Caballero-Navarro

  • M. T. Gómez-Casares

  • E. Magro

  • G. Carreño-Tarragona

  • M. A. Cortés-Vázquez

  • R. Pérez López

  • V. García-Gutiérrez

  • M. S. Noya-Pereira

  • J. M. Alonso-Dominguez

  • C. Sierra- Aisa

  • L. Fox

  • C. García Hernández

  • J. M. Guerra

  • E. Cerezo

  • M. Gasior

  • M. Santaliestra

  • I. Díez

  • M. V. Cuevas

  • L. Sanz

  • I. Pastor

  • R. Stuckey

  • P. Vélez

  • C. Auría-Caballero

  • A. Alvarez-Larrán

  • May 7, 2026

  • 0 min

Share

Clinical Report: The Role of Thrombotic Events in Disease Advancement

Overview

Revise to include specific survival rates for ET and PV patients with and without AT.

Background

Myeloproliferative neoplasms (MPNs) such as ET and PV are characterized by a high incidence of thrombotic events, which can influence patient outcomes. Understanding the relationship between these thrombotic events and disease progression is crucial for improving patient management and treatment strategies.

Data Highlights

ConditionThrombotic EventsMedian Survival Rate (Years)p-value
ET with AT24814.4< 0.001
ET without Thrombosis015.8
PV with AT18114< 0.001
PV without Thrombosis019

Key Findings

  • In ET patients, 10.4% experienced thrombotic events, with AT linked to significantly lower survival rates.
  • In PV patients, 10.9% had thrombotic events, with AT also associated with reduced survival.
  • JAK2V617F mutation status influenced the risk of mortality and second cancers.
  • Thrombotic events did not correlate with the progression to myelofibrosis in either ET or PV cohorts.
  • Second cancers occurred in 7.18% of ET patients and 8.9% of PV patients, with no significant association with thrombosis.

Clinical Implications

Healthcare providers should closely monitor MPN patients for thrombotic events, particularly those with AT, as these events are associated with poorer survival outcomes. Risk stratification based on thrombotic history and JAK2 mutation status may enhance patient management strategies.

Conclusion

The findings underscore the importance of recognizing thrombotic events in MPN patients, as they are significant predictors of mortality and disease progression, particularly in those with arterial thrombosis.

Related Resources & Content

  1. Blood Cancer Journal, 2024 -- Thrombotic Events in Myeloproliferative Neoplasms: An Analysis of Their Effects on Myelofibrosis, Mortality Rates, and Solid Tumor Development
  2. Blood Cancer Journal, 2021 -- Mutations and thrombosis in essential thrombocythemia
  3. Blood Cancer Journal, 2023 -- A Study of 1,000 Patients with Essential Thrombocythemia: Insights from the Florence-CRIMM Cohort
  4. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management - PubMed
  5. Blood Cancer Journal — Models for Predicting Essential Thrombocythemia Based on Two Longitudinal Studies with 2000 Participants
  6. Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors
  7. Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talk
  8. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management - PubMed

Original Source(s)

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera

  • by A. Angona, B. Cuevas, M. Pérez-Encinas, F. Ferrer-Marin, A. Senín, E. Arellano-Rodrigo, J. C. Hernández-Boluda, M. I. Mata Vázquez, G. Caballero-Navarro, M. T. Gómez-Casares, E. Magro, G. Carreño-Tarragona, M. A. Cortés-Vázquez, R. Pérez López, V. García-Gutiérrez, M. S. Noya-Pereira, J. M. Alonso-Dominguez, C. Sierra- Aisa, L. Fox, C. García Hernández, J. M. Guerra, E. Cerezo, M. Gasior, M. Santaliestra, I. Díez, M. V. Cuevas, L. Sanz, I. Pastor, R. Stuckey, P. Vélez, C. Auría-Caballero, A. Alvarez-Larrán

  • May 7, 2026

Related Content

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities